Trial Profile
A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine quadrivalent-Seqirus (Primary) ; DTaP vaccine
- Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections; Influenza virus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis; Seqirus
- 10 Aug 2021 Austria, Brazil, Finland, Norway and South Africa were the planned location, as per European Clinical Trials Database record.
- 01 Jul 2021 Results published in The Lancet Infectious Diseases
- 22 Aug 2018 Status changed from active, no longer recruiting to completed.